Microcap Ledger Apimeds Pharmaceuticals US, Inc. $APUS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Matawan, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 1,509,118 [10-Q 2026-08-14]
What the company doesAI summary of filing
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company developing Apitox, a purified bee venom-based therapeutic administered by intradermal injection. The company is primarily focused on advancing Apitox for the treatment of inflammation and pain management symptoms associated with knee osteoarthritis (OA) through a planned Phase III clinical trial, with secondary interest in multiple sclerosis (MS) through non-registered corporate sponsorship studies. Apitox is currently marketed in South Korea as Apitoxin by an affiliated company for OA treatment. The company does not yet generate revenue from product sales and is pre-commercialization, relying on clinical development activities. [10-K 2026-05-04]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$55.23M | −$7.73M | $278.4K | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$6.00M | −$8.93M | $1.64M | [10-K 2026-05-04] |
| FY ended Dec 2024 | — | −$1.39M | −$733.5K | $3.5K | [10-K 2026-05-04] |
- Quarterly cash burn
- −$3.87M
- Cash runway Estimate
- ~0.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-15 | 8,193,398 | [10-K/A 2025-05-02] |
| 2025-05-19 | 11,575,983 | [10-Q 2025-05-20] |
| 2025-08-18 | 12,575,983 | [10-Q 2025-08-19] |
| 2025-11-12 | 12,575,983 | [10-Q 2025-11-12] |
| 2026-04-30 | 12,575,983 | [10-K 2026-05-04] |
| 2026-05-26 | 15,091,177 | [10-Q 2026-05-26] |
| 2026-08-12 | 1,509,118 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2024-09-25; declared effective 2025-05-05 [S-1 2024-09-25]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-04-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-04-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 8-K | Director or officer change |
| 2026-09-29 | 8-K | Other events |
| 2026-09-23 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-09-11 | 8-K | Material agreement entered; Director or officer change |
| 2026-08-21 | 8-K | Material agreement entered |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Other events |
| 2026-07-13 | 8-K | Other events |
| 2026-05-26 | 10-Q | Quarterly report |
| 2026-05-15 | NT 10-Q | Notice of late quarterly report |
| 2026-05-07 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-05 | 8-K | Director or officer change |
Alerts for $APUS
Email me when Apimeds Pharmaceuticals US, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.